KRYS - Krystal Biotech to Participate in H.C. Wainwright and Guggenheim Investor Conferences
PITTSBURGH, March 24, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. , (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapy, today announced that Krish S. Krishnan, Chairman and Chief Executive Officer, will participate in H.C. Wainwright’s Gene Therapy and Gene Editing Conference and Guggenheim’s 3 rd Annual Genomic Medicines and Rare Disease Day.
Details for the events are as follows:
H.C. Wainwright Gene Therapy and Gene Editing Conference |
Presentation Date: |
Wednesday, March 30, 2022 |
Presentation Time: |
7:00 a.m. EDT |
Webcast Link: |
https://journey.ct.events/view/5be9c8c9-116d-4777-b0f7-afc3aa88fd82 |
A webcast of the presentation will be available for 90 days beginning at 7:00 a.m. on March 30. It will also be posted in the Investors section of the Krystal Biotech website .
Guggenheim 3 rd Annual Genomic Medicines and Rare Disease Day |
Fireside Chat Date: |
Thursday, March 31, 2022 |
Fireside Chat Time: |
2-2:45 p.m. EDT |
Webcast and Replay Link: |
https://kvgo.com/guggenheim/krystal-biotech-inc-march-2022 |
A replay of the fireside chat will be available via a link on the Krystal Biotech website approximately 48 hours after the event and will be viewable for 1 year.
About Krystal Biotech
Krystal Biotech, Inc. (NASDAQ: KRYS) is a pivotal-stage gene therapy company leveraging its proprietary, redosable gene therapy platform and in-house manufacturing capabilities to potentially bring life-changing treatment options to patients with serious diseases, including rare diseases in skin, lung, and other areas. For more information, please visit http://www.krystalbio.com and follow @KrystalBiotech on LinkedIn and Twitter .
CONTACTS:
Investors:
Whitney Ijem
Krystal Biotech
wijem@krystalbio.com
Media:
Tiffany Hamilton
Krystal Biotech
thamilton@krystalbio.com
Source: Krystal Biotech, Inc.